---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066382"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:10:07.526463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's

## Summary
- Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.
- Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.
- EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.
- CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.
- CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1.

## SEC filing metadata
- accession: 0000950170-25-066382
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/0000950170-25-066382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/cgem-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066382
- JSON: https://secwatch.observer/filing/0000950170-25-066382.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.